Citadel Advisors
TLSIW icon

Citadel Advisors’s TriSalus Life Sciences Warrant TLSIW Stock Holding History

Citadel Advisors’s Portfolio TLSIW Stock Details TLSIW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$78.2K Sell
65,190
-13,093
-17% -$17.6K ﹤0.01% 12191
2025
Q4 		$129K Sell
78,283
-48,593
-38% -$61.9K ﹤0.01% 11438
2025
Q3 		$199K Buy
126,876
+103,336
+439% +$188K ﹤0.01% 11271
2025
Q2 		$30.4K Buy
+23,540
New +$33.4K ﹤0.01% 11973
2021
Q3 		– Sell
-185,587
Closed -$184K – 14655
2021
Q2 		$184K Sell
185,587
-338
-0.2% -$334 ﹤0.01% 12256
2021
Q1 		$205K Buy
+185,925
New +$336K ﹤0.01% 11648

Other funds holding TLSIW

Cerity Partners
Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
FBCM
Fort Baker Capital Management Larkspur, California $1.27B AUM 25.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Citadel Advisors's TLSIW Position: Q1 2026 in Review

Citadel Advisors reduced its TriSalus Life Sciences Warrant (TLSIW) stake by 17% in Q1 2026, selling an estimated $17.6K and leaving 65,190 shares worth $78.2K. The position accounts for ﹤0.01% of the portfolio, ranked #12191.

Citadel Advisors first reported a position in TLSIW in Q1 2021 and has held it in 6 quarters since. The position peaked at $205K in Q1 2021. 7 funds tracked by Wall St. Rank hold TLSIW as of Q1 2026.

  • Citadel Advisors held 65,190 shares of TriSalus Life Sciences Warrant worth $78.2K as of Q1 2026.
  • Citadel Advisors sold 13,093 TriSalus Life Sciences Warrant shares in Q1 2026, an estimated $17.6K.
  • TriSalus Life Sciences Warrant made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #12191 holding.
  • Citadel Advisors first reported a position in TriSalus Life Sciences Warrant in Q1 2021 and has held it in 6 quarters since.
  • Citadel Advisors's TriSalus Life Sciences Warrant position peaked at $205K in Q1 2021.
  • 7 funds tracked by Wall St. Rank held TriSalus Life Sciences Warrant as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.